ZITHROMAX

Compare ZITHROMAX  to:
Compare
Compare

Generic Name for ZITHROMAX

Azithromycin (as dihydrate) 250mg, 500mg, 600mg; tabs.

Legal Classification:

Rx

Pharmacological Class for ZITHROMAX

Macrolide (azalide).

Manufacturer of ZITHROMAX

Pfizer Labs

Indications for ZITHROMAX

Mild to moderate susceptible infections including acute bacterial exacerbations of COPD, acute bacterial sinusitis, acute otitis media, community-acquired pneumonia, pharyngitis/tonsillitis, uncomplicated skin and skin structure, urethritis, cervicitis, chancroid in men. Mycobacterium avium complex (MAC) disease: see literature.

Adult dose for ZITHROMAX

Use packets only for doses equal to 1gram. COPD: 500mg once daily for 3 days; or 500mg once daily for 1 day, then 250mg once daily for 4 days. Sinusitis: 500mg once daily for 3 days. Community-acquired pneumonia, pharyngitis/tonsillitis, skin and skin structure: 500mg once daily for 1 day, then 250mg once daily for 4 days. Nongonococcal urethritis, cervicitis, chancroid: 1g as a single dose. Urethritis, cervicitis due to N. gonorrhoeae: 2g as a single dose. MAC: see literature.

Children's dosing for ZITHROMAX

Use oral susp (not packets). Otitis media: <6 months: not recommended; ≥6 months: 30mg/kg as a single dose (max 1.5g); or 10mg/kg (max 500mg) once daily for 3 days; or 10mg/kg (max 500mg) once then 5mg/kg (max 250mg) per day for 4 days. Sinusitis: <6 months: not recommended; ≥6 months: 10mg/kg (max 500mg) once daily for 3 days. Community-acquired pneumonia: <6 months: not recommended; ≥6 months: 10mg/kg (max 500mg) once daily for 1 day, then 5mg/kg (max 250mg) once daily for 4 days. Pharyngitis/tonsillitis: <2 yrs: not recommended; ≥2 yrs: 12mg/kg (max 500mg) once daily for 5 days. MAC prophylaxis: see literature.

Also:

Contraindications for ZITHROMAX

Ketolide or related allergy.

Warnings/Precautions for ZITHROMAX

Pneumonia: oral treatment is for mild, community-acquired cases suitable for outpatient therapy only. Hepatic or renal impairment. Hypersensitivity reactions may recur after initial successful symptomatic treatment. Pregnancy (Cat.B). Nursing mothers.

Interactions for ZITHROMAX

Avoid concomitant aluminum- or magnesium-containing antacids. Monitor digoxin, cyclosporine, ergots, hexobarbital, phenytoin, warfarin. Monitor for azithromycin toxicity (eg, liver dysfunction, ototoxicity) with nelfinavir.

Adverse Reactions for ZITHROMAX

GI upset, abdominal pain, rash, chest pain; rare: allergy (eg, angioedema, cholestatic jaundice).

How is ZITHROMAX supplied?

Tabs—30
Z-Pak (6 x 250mg tabs)—3
Tri-Pak (3 x 500mg tabs)—3
Susp 100mg/5mL—15mL
200mg/5mL—15mL, 22.5mL, 30mL
Single Dose Packets—3, 10
Inj (500mg vials)—10

Related Disease:

Infections, bacterial~systemic antiinfectives
Pneumonia
Sinusitis

Related Resources

Tygacil labeling updated to include increased mortality risk

September 01, 2010

The FDA is reminding healthcare professionals that intravenous Tygacil (tigecycline, from Pfizer) can increase mortality risk in the treatment of serious bacterial infections.

Phase 3 study of torezolid for acute bacterial skin and skin structure infections

August 30, 2010

Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

FDA warns of eosinophilic pneumonia risk with Cubicin

July 29, 2010

The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia while receiving the antibiotic Cubicin (daptomycin, from Cubist).

FDA warns of counterfeit Tamiflu product

June 18, 2010

The FDA has warned consumers about a potentially harmful product represented as "Generic Tamiflu" sold over the Internet.

Claris Lifesciences' intravenous medications recalled

June 01, 2010

The FDA has notified healthcare professionals not to use the intravenous medications, metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences due to contamination.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions